Red blood cells in type 2 diabetes impair cardiac post-ischemic recovery through an arginase-dependent modulation of nitric oxide synthase and reactive oxygen …
JACC: Basic to Translational Science, 2018•jacc.org
This study tested the hypothesis that red blood cell (RBC) arginase represents a potential
therapeutic target in ischemia-reperfusion in type 2 diabetes. Post-ischemic cardiac recovery
was impaired in hearts from db/db mice compared with wild-type hearts. RBCs from mice
and patients with type 2 diabetes attenuated post-ischemic cardiac recovery of nondiabetic
hearts. This impaired cardiac recovery was reversed by inhibition of RBCs arginase or nitric
oxide synthase. The results suggest that RBCs from type 2 diabetics impair cardiac …
therapeutic target in ischemia-reperfusion in type 2 diabetes. Post-ischemic cardiac recovery
was impaired in hearts from db/db mice compared with wild-type hearts. RBCs from mice
and patients with type 2 diabetes attenuated post-ischemic cardiac recovery of nondiabetic
hearts. This impaired cardiac recovery was reversed by inhibition of RBCs arginase or nitric
oxide synthase. The results suggest that RBCs from type 2 diabetics impair cardiac …
Summary
This study tested the hypothesis that red blood cell (RBC) arginase represents a potential therapeutic target in ischemia-reperfusion in type 2 diabetes. Post-ischemic cardiac recovery was impaired in hearts from db/db mice compared with wild-type hearts. RBCs from mice and patients with type 2 diabetes attenuated post-ischemic cardiac recovery of nondiabetic hearts. This impaired cardiac recovery was reversed by inhibition of RBCs arginase or nitric oxide synthase. The results suggest that RBCs from type 2 diabetics impair cardiac tolerance to ischemia-reperfusion via a pathway involving arginase activity and nitric oxide synthase-dependent oxidative stress.
jacc.org